Cargando…
3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128271/ https://www.ncbi.nlm.nih.gov/pubmed/32247821 http://dx.doi.org/10.1016/j.phrs.2020.104779 |
| _version_ | 1783516527950036992 |
|---|---|
| author | Sisay, Mekonnen |
| author_facet | Sisay, Mekonnen |
| author_sort | Sisay, Mekonnen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7128271 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71282712020-04-08 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials Sisay, Mekonnen Pharmacol Res Article Elsevier Ltd. 2020-06 2020-04-02 /pmc/articles/PMC7128271/ /pubmed/32247821 http://dx.doi.org/10.1016/j.phrs.2020.104779 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Sisay, Mekonnen 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
| title | 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
| title_full | 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
| title_fullStr | 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
| title_full_unstemmed | 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
| title_short | 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |
| title_sort | 3cl(pro) inhibitors as a potential therapeutic option for covid-19: available evidence and ongoing clinical trials |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128271/ https://www.ncbi.nlm.nih.gov/pubmed/32247821 http://dx.doi.org/10.1016/j.phrs.2020.104779 |
| work_keys_str_mv | AT sisaymekonnen 3clproinhibitorsasapotentialtherapeuticoptionforcovid19availableevidenceandongoingclinicaltrials |